NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

KTTA

Pasithea Therapeutics Corp

May 09 • 12:10PM ET

0.8408

Dollar change -0.1192
Percentage change -12.42	%

Healthcare • Biotechnology • USA • NASD

Peers: CMPS MNMD ATAI CYBN GHRS RLMD PALI SLS WKSP

| Held by: PSIL

Index	-	P/E	-	EPS (ttm)	-12.69	Insider Own	19.08%	Shs Outstand	2.96M	Perf Week	-39.94%
Market Cap	2.49M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.39M	Perf Month	-22.86%
Income	-13.90M	PEG	-	EPS next Q	-	Inst Own	2.73%	Short Float	17.45%	Perf Quarter	-55.98%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	30.23%	Short Ratio	0.08	Perf Half Y	-77.99%
Book/sh	10.60	P/B	0.08	EPS next Y	-	ROA	-65.93%	Short Interest	0.42M	Perf Year	-87.85%
Cash/sh	2.34	P/C	0.36	EPS next 5Y	-	ROE	-72.83%	52W Range	0.91 - 7.69	Perf YTD	-73.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-282.28%	ROI	-94.06%	52W High	-89.07%	Beta	0.50
Dividend TTM	-	Quick Ratio	6.58	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	-7.60%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	6.58	EPS Y/Y TTM	4.70%	Oper. Margin	-	RSI (14)	31.73	Volatility	51.83% 25.83%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	50.40%	Payout	-	Rel Volume	0.48	Prev Close	0.96
Sales Surprise	-33.33%	EPS Surprise	-5.88%	Sales Q/Q	-	Earnings	-	Avg Volume	5.54M	Price	0.84
SMA20	-41.00%	SMA50	-34.87%	SMA200	-71.88%	Trades		Volume	1,172,270	Change	-12.42%

May-07-25 05:00PM	Pasithea Therapeutics Announces Closing of $5 Million Public Offering (GlobeNewswire) -25.66% -15.04%
11:35AM	Pasithea Therapeutics 3.57M share Secondary priced at $1.40 (TipRanks)
May-06-25 11:10AM	Pasithea Therapeutics Announces Pricing of $5 Million Public Offering (GlobeNewswire) +7.04%
07:03AM	Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 (GlobeNewswire)
Apr-29-25 07:02AM	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients (GlobeNewswire)
07:02AM	Loading…
Apr-24-25 07:02AM	Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting (GlobeNewswire) +5.52%
Apr-10-25 07:02AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire) +46.79%
Mar-24-25 06:59AM	Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference (GlobeNewswire)
Feb-05-25 06:59AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire) +31.73%
Jan-14-25 08:02AM	Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 (GlobeNewswire)
Nov-20-24 07:02AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-26-24 06:44PM	Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +52.15%
07:02AM	Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-09-24 08:01AM	Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies (GlobeNewswire)
Sep-03-24 08:02AM	Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board (GlobeNewswire) +6.57%
09:11AM	Loading…
Aug-28-24 09:11AM	Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jun-25-24 12:52PM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023 (InvestorPlace) +6.64%
Jun-13-24 06:59AM	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial (GlobeNewswire)
May-28-24 06:59AM	Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 09:53AM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-29-24 07:59AM	Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-24-24 07:59AM	Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers (GlobeNewswire)
Apr-15-24 11:00AM	11 Undervalued Stocks for Less Than $50 in April 2024 (Investopedia)
Feb-13-24 07:59AM	Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 (GlobeNewswire) +8.95%
Jan-08-24 07:59AM	Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position (GlobeNewswire) +5.03%
Jan-02-24 08:35AM	Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients (GlobeNewswire) +8.78%
Dec-28-23 05:00PM	Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 (GlobeNewswire) -5.13%
Dec-19-23 05:19PM	Pasithea Therapeutics Announces Results from 2023 Annual Meeting (GlobeNewswire) -6.06% -13.61%
Dec-13-23 09:03AM	Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today? (InvestorPlace)
Dec-11-23 11:18AM	Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today? (InvestorPlace) +47.42%
08:01AM	Loading…
08:01AM	Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models (GlobeNewswire)
Nov-29-23 04:27PM	Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) +6.63% -7.91%
07:59AM	Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development (GlobeNewswire)
Nov-09-23 07:59AM	Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 5 1 Integrin for the Treatment of both Sporadic and Familial ALS (GlobeNewswire)
Sep-14-23 08:30AM	Pasithea Therapeutics Corp. Announces Final Results of Tender Offer (GlobeNewswire)
Sep-07-23 04:14PM	Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -13.18%
Aug-01-23 07:59AM	Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in 5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting 5 integrin results in improved survival and motor function (GlobeNewswire)
Jul-31-23 06:00AM	The Psychedelics Stock Universe Is Shrinking, Despite the Hype (Bloomberg)
Jul-20-23 08:43AM	Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash (GlobeNewswire) +25.88%
08:40AM	Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc. (GlobeNewswire)
Jul-13-23 09:14AM	Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood (Exec Edge)
Jun-30-23 09:28AM	Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors (GlobeNewswire)
Jun-29-23 02:50PM	Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +11.24%
08:29AM	Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004 (GlobeNewswire)
Jun-06-23 04:30PM	Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc. (GlobeNewswire)
Jun-05-23 09:00AM	Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +25.00%
Jun-01-23 07:57AM	Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference (GlobeNewswire)
May-14-23 08:13AM	Pasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022) (Simply Wall St.)
May-03-23 08:26AM	Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire)
Mar-02-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting (GlobeNewswire)
Feb-23-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) (GlobeNewswire) -5.64%
Feb-16-23 07:30AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award (GlobeNewswire)
Jan-18-23 08:00AM	Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004 (GlobeNewswire)
Dec-14-22 05:18PM	Majority of Stockholders Support Pasithea Directors at Special Meeting (GlobeNewswire)
Dec-12-22 07:00AM	Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group (GlobeNewswire) -8.22%
Dec-07-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Dec-06-22 08:00AM	Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference (GlobeNewswire)
Nov-28-22 07:05PM	Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time (GlobeNewswire)
Nov-22-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Oct-27-22 09:50AM	A New BioTech Research Race Is Focused On Improving Life For MS Patients (News Direct)
Oct-17-22 08:00AM	Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium (GlobeNewswire) -11.20%
Oct-14-22 09:48AM	Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive (Benzinga)
Oct-13-22 04:00PM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics (Business Wire)
Oct-12-22 08:00AM	Pasithea Therapeutics Acquires AlloMek Therapeutics (GlobeNewswire)
07:31AM	EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition (Benzinga)
Oct-10-22 09:39AM	New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope (News Direct)
Oct-03-22 06:03PM	Pasithea Therapeutics to Call Special Meeting of Stockholders (GlobeNewswire)
09:09AM	Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis (News Direct)
Sep-28-22 09:00AM	Investor Group Sends Letter to Pasithea Therapeutics Board of Directors (Business Wire)
Sep-20-22 08:00AM	Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors (GlobeNewswire)
Sep-15-22 08:00AM	Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz (GlobeNewswire)
Sep-12-22 11:53AM	Here's Why We're Not Too Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation (Simply Wall St.)
Sep-09-22 10:32AM	Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 09:30AM	Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics (Business Wire)
Aug-24-22 08:00AM	Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting (Business Wire)
Aug-18-22 08:00AM	Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference (GlobeNewswire)
Aug-11-22 08:00AM	Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis (GlobeNewswire) +6.83%
07:30AM	EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox (Benzinga)
Aug-05-22 09:00AM	Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting (Business Wire)
Aug-02-22 07:00AM	Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Groups Unjustified Campaign (GlobeNewswire)
Jul-14-22 08:00AM	Pasithea Therapeutics Awarded a Drug Development Research Grant (GlobeNewswire)
Jun-23-22 09:00AM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5 (Business Wire)
08:00AM	Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond (GlobeNewswire)
Jun-22-22 08:00AM	Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC (GlobeNewswire)
07:30AM	EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition (Benzinga)
Apr-14-22 04:15PM	Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022 (GlobeNewswire) +9.76% -8.89%
Apr-05-22 03:57PM	We're Not Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn (Simply Wall St.)
Mar-30-22 04:15PM	Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022 (GlobeNewswire) -7.14%
Mar-08-22 08:00AM	Pasithea Therapeutics Announces Collaboration with The Glimpse Group (GlobeNewswire) +7.08%
07:30AM	EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders (Benzinga)
Feb-24-22 08:00AM	Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022 (GlobeNewswire)
Feb-09-22 08:00AM	Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger (GlobeNewswire)
Feb-03-22 08:00AM	Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis (GlobeNewswire) -6.40%
Jan-26-22 08:00AM	Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments (GlobeNewswire)
Dec-23-21 11:35AM	KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today (InvestorPlace) +36.73%
07:36AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Dec-21-21 08:00AM	Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom (GlobeNewswire) +9.72%
Dec-01-21 08:00AM	Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada (GlobeNewswire) -8.59%
Nov-29-21 05:45PM	Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules (GlobeNewswire) +5.99% -15.06%
Nov-24-21 08:52AM	Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules (GlobeNewswire) -28.75%

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

Dollar change +0.01
Percentage change 0.64	%

ATNF 180 Life Sciences Corp daily Stock Chart

Peers: AMGN REGN BIIB ABBV VRTX GILD BMRN INCY ALNY NBIX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-6.38	Insider Own	79.08%	Shs Outstand	3.18M	Perf Week	-10.00%
Market Cap	5.60M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.41M	Perf Month	43.73%
Income	-14.18M	PEG	-	EPS next Q	-	Inst Own	31.53%	Short Float	29.11%	Perf Quarter	-22.86%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	1.14%	Short Ratio	0.83	Perf Half Y	-65.93%
Book/sh	2.91	P/B	0.37	EPS next Y	-	ROA	-31.82%	Short Interest	0.12M	Perf Year	-46.27%
Cash/sh	0.89	P/C	1.22	EPS next 5Y	-	ROE	-135.21%	52W Range	0.66 - 17.75	Perf YTD	-40.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	55.37%	ROI	-153.15%	52W High	-93.92%	Beta	-
Dividend TTM	-	Quick Ratio	1.47	Sales past 5Y	0.00%	Gross Margin	-	52W Low	64.18%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	1.47	EPS Y/Y TTM	90.08%	Oper. Margin	-	RSI (14)	54.29	Volatility	17.29% 14.50%
Employees	3	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	1520.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-68.51%	Payout	-	Rel Volume	0.44	Prev Close	1.07
Sales Surprise	-	EPS Surprise	84.62%	Sales Q/Q	-	Earnings	-	Avg Volume	144.60K	Price	1.08
SMA20	11.20%	SMA50	6.74%	SMA200	-40.86%	Trades		Volume	27,410	Change	0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-21	Initiated	Maxim Group	Buy	$11

May-01-25 09:30AM	180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction (ACCESSWIRE) +49.44%
Apr-30-25 08:30AM	180 Life Sciences Corp. Announces Share Repurchase (ACCESSWIRE)
Dec-27-24 09:00AM	180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules (ACCESSWIRE) -24.03%
Dec-12-24 08:00AM	180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules (ACCESSWIRE) -14.16%
Dec-04-24 08:00AM	180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors (ACCESS Newswire)
08:00AM	Loading…
Oct-31-24 08:00AM	180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration (ACCESSWIRE)
Oct-29-24 08:00AM	180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors (ACCESSWIRE)
Oct-25-24 09:00AM	Elray Resources Announces Strategic Sale of Crypto iGaming Technology (GlobeNewswire) +9.79%
Oct-17-24 10:52AM	180 Life Sciences' Brave Decision To Switch to the iGaming Industry (GuruFocus.com) -33.08%
Oct-16-24 08:00AM	180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform (ACCESSWIRE) +325.66%
Oct-09-24 08:30AM	180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector (ACCESSWIRE) +16.10%
Oct-03-24 08:30AM	180 Life Sciences Corp. - Corporate Updates (ACCESSWIRE)
Sep-12-24 04:15PM	180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer (GlobeNewswire) +13.64% -9.50%
Jul-30-24 08:00AM	180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake (GlobeNewswire)
Jul-23-24 08:00AM	180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire)
08:30AM	Loading…
Jul-02-24 08:30AM	180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire) +10.00%
May-16-24 11:53AM	ATNF Stock Earnings: 180 Life Sciences Reported Results for Q1 2024 (InvestorPlace) -14.95%
Mar-14-24 08:30AM	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-26-24 07:00AM	180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire) +5.49%
Dec-04-23 09:00AM	180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives (GlobeNewswire)
Nov-28-23 09:00AM	180 Life Sciences Announces Review of Strategic Alternatives (GlobeNewswire) +7.70%
Aug-14-23 04:29PM	180 Life Sciences Corp. Announces Closing of $3 Million Public Offering (GlobeNewswire)
Aug-10-23 08:46AM	180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering (GlobeNewswire) -16.73%
Aug-07-23 09:00AM	180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake (GlobeNewswire)
Aug-03-23 08:00AM	180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytrens Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA (GlobeNewswire)
Jul-31-23 08:00AM	180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite (GlobeNewswire)
Apr-10-23 04:30PM	180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Apr-05-23 01:00PM	180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -19.66%
Feb-27-23 08:30AM	180 Life Sciences Announces Presentation at the Gordon Conference (GlobeNewswire) +5.51%
Feb-23-23 07:30AM	180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytrens Disease Treatment and Application (GlobeNewswire) -10.82%
04:30PM	Loading…
Feb-22-23 04:30PM	180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial (GlobeNewswire)
Jan-25-23 08:45AM	180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytrens Disease (GlobeNewswire) +33.75%
Jan-17-23 08:00AM	180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom (GlobeNewswire)
Jan-05-23 08:30AM	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +12.33%
Jan-04-23 08:30AM	180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytrens Disease (GlobeNewswire) -17.36%
Dec-29-22 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders (GlobeNewswire) +13.86%
Dec-23-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -21.52%
Dec-20-22 02:11PM	180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -15.85%
Dec-16-22 09:00AM	180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire) -11.67%
Nov-30-22 05:00PM	180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytrens Contracture (GlobeNewswire)
Nov-21-22 08:30AM	180 Life Sciences to Participate in A.G.P.s Virtual Biotech Conference to be Held November 30 December 1, 2022 (GlobeNewswire) -12.87%
Nov-15-22 12:37PM	CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease (GlobeNewswire) +12.02%
08:00AM	Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease (GlobeNewswire)
Sep-26-22 08:30AM	180 Life Sciences Issues Letter to Stockholders (GlobeNewswire)
Aug-22-22 08:30AM	180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder (GlobeNewswire) -10.53%
Jul-27-22 08:30AM	180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp. (GlobeNewswire)
Jul-21-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering (GlobeNewswire) +5.65%
Jul-18-22 08:30AM	180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering (GlobeNewswire)
Jun-22-22 04:05PM	180 Life Sciences Corp. Issues Letter to Stockholders (GlobeNewswire)
Jun-14-22 04:15PM	180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytrens Disease (GlobeNewswire) -34.00%
May-31-22 08:30AM	180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytrens Disease (GlobeNewswire) +18.25%
May-02-22 08:00AM	REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology (GlobeNewswire) -20.75%
Apr-29-22 06:32PM	180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology (GlobeNewswire) +22.54%
Feb-17-22 08:30AM	180 Life Sciences Corp. Forms Scientific Advisory Board (GlobeNewswire) -6.61%
Jan-31-22 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders (GlobeNewswire) +7.12%
Dec-28-21 11:00AM	180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022 (GlobeNewswire) -5.75%
Dec-15-21 08:15AM	180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases (GlobeNewswire)
Dec-12-21 06:06AM	Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares (Simply Wall St.)
Dec-10-21 05:15PM	180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares (GuruFocus.com)
Dec-06-21 08:15AM	180 Life Sciences Provides Follow-Up Information on Oxford University and the Companys Successful Dupuytrens Phase 2b Clinical Trial Results (GlobeNewswire) +7.95%
Dec-01-21 02:45PM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial (GlobeNewswire) -20.85%
02:26PM	180 Life Sciences: Positive Data From Dupuytrens Disease Study Could Be a Big Catalyst, Says Analyst (TipRanks)
Nov-22-21 08:30AM	180 Life Sciences Corp. Expands Patent Portfolio (GlobeNewswire)
Nov-18-21 08:15AM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium (GlobeNewswire) +9.86%
Nov-03-21 12:06PM	180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer (GlobeNewswire)
Oct-26-21 08:30AM	180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules (GlobeNewswire)
Sep-30-21 08:30AM	180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio (GlobeNewswire) +5.66%
Sep-20-21 08:00AM	Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications (GlobeNewswire) -6.29%
Aug-30-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)
Aug-24-21 08:30AM	180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement (GlobeNewswire)
Aug-19-21 09:00AM	180 Life Sciences Corp. Announces $15.0 Million Private Placement (GlobeNewswire) -25.73%
08:10AM	Is 180 Life Sciences Corp.'s (NASDAQ:ATNF) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Aug-02-21 08:00AM	Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021 (GlobeNewswire)
Jul-29-21 08:00AM	180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-28-21 08:15AM	180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue (GlobeNewswire)
Jul-20-21 08:00AM	180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) (GlobeNewswire)
Jul-12-21 09:51AM	180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2) (GlobeNewswire) +9.75%
Jul-07-21 08:00AM	180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal (GlobeNewswire)
Jun-28-21 08:15AM	180 Life Sciences Joins Russell Microcap® Index (GlobeNewswire)
08:00AM	180 Life Sciences Files Plan with Nasdaq Related to Delayed Quarterly Report on Form 10-Q and Form 10-K (GlobeNewswire)
Jun-10-21 09:12AM	180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors (GlobeNewswire)
Jun-01-21 08:00AM	180 Life Sciences Corp. to Present at LD Micro Invitational XI (GlobeNewswire) +8.90%
May-28-21 08:00AM	180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors (GlobeNewswire) +7.96%
May-21-21 04:45PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q (GlobeNewswire) +10.61%
Apr-20-21 08:00AM	180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytrens Disease Trial (GlobeNewswire)
Apr-19-21 05:00PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K (GlobeNewswire) -16.53%
Apr-14-21 08:15AM	180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021 (GlobeNewswire)
Mar-26-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics (GlobeNewswire) +18.57%
Mar-25-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters (GlobeNewswire) +13.65%
Mar-24-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)
Mar-08-21 01:30PM	180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC (GlobeNewswire) +5.46%
Feb-24-21 04:00PM	180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement (GlobeNewswire) +11.06% -10.37%
Feb-19-21 09:00AM	180 Life Sciences Corp. Announces $11.7 Million Private Placement (GlobeNewswire) -13.46%
Feb-17-21 12:00AM	Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)? (Simply Wall St.) -5.45%
Jan-11-21 08:00AM	180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference (Newsfile) +5.06%
Jan-05-21 02:50PM	180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference (GlobeNewswire) +7.17%
Dec-03-20 11:08AM	180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST (GlobeNewswire)
Nov-24-20 10:00AM	180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020 (GlobeNewswire) -6.93%
Nov-23-20 08:30AM	180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants (GlobeNewswire) +17.44%
Nov-17-20 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

Open in Screener

BCAB

BioAtla Inc

May 09 • 12:08PM ET

0.4550

Dollar change -0.0180
Percentage change -3.81	%

Healthcare • Biotechnology • USA • NASD

Peers: ADPT ALXO IDYA IMTX AGEN TCRX SRRK ANVS HOOK

| Held by: VTI VXF IWC BTEC

Index	-	P/E	-	EPS (ttm)	-1.22	Insider Own	22.31%	Shs Outstand	58.40M	Perf Week	-18.46%
Market Cap	26.58M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	0.00%	Shs Float	45.39M	Perf Month	49.52%
Income	-61.88M	PEG	-	EPS next Q	-0.29	Inst Own	38.39%	Short Float	8.94%	Perf Quarter	1.38%
Sales	11.00M	P/S	2.42	EPS this Y	19.44%	Inst Trans	-18.55%	Short Ratio	5.57	Perf Half Y	-78.02%
Book/sh	0.01	P/B	48.56	EPS next Y	4.60%	ROA	-97.07%	Short Interest	4.06M	Perf Year	-85.28%
Cash/sh	0.55	P/C	0.82	EPS next 5Y	8.86%	ROE	-246.21%	52W Range	0.24 - 3.32	Perf YTD	-23.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.97%	ROI	-11311.88%	52W High	-86.30%	Beta	1.00
Dividend TTM	-	Quick Ratio	2.35	Sales past 5Y	-46.70%	Gross Margin	92.11%	52W Low	89.58%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	2.35	EPS Y/Y TTM	51.11%	Oper. Margin	-610.00%	RSI (14)	55.22	Volatility	14.04% 12.55%
Employees	76	Debt/Eq	1.00	Sales Y/Y TTM	-	Profit Margin	-562.51%	Recom	1.67	Target Price	5.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	45.53%	Payout	-	Rel Volume	0.74	Prev Close	0.47
Sales Surprise	-	EPS Surprise	11.35%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	727.85K	Price	0.46
SMA20	8.49%	SMA50	23.53%	SMA200	-59.73%	Trades		Volume	233,518	Change	-3.81%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-22	Initiated	JMP Securities	Mkt Outperform	$17
May-05-22	Downgrade	Credit Suisse	Outperform → Neutral	$35 → $5
Mar-21-22	Initiated	H.C. Wainwright	Buy	$25
Oct-15-21	Resumed	BTIG Research	Buy	$68
Jun-28-21	Initiated	ROTH Capital	Buy	$75
May-05-21	Resumed	Credit Suisse	Outperform	$68
Apr-26-21	Resumed	Credit Suisse	Outperform	$68
Jan-11-21	Initiated	JP Morgan	Overweight	$45
Jan-11-21	Initiated	Jefferies	Buy	$51
Jan-11-21	Initiated	Credit Suisse	Outperform	$49
Jan-11-21	Initiated	BTIG Research	Buy	$47

Show Previous Ratings

May-07-25 03:21AM	BioAtla Inc (BCAB) Q1 2025 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... (GuruFocus.com) -5.74%
May-06-25 04:05PM	BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire) -8.19%
Apr-30-25 08:00AM	BioAtla to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
Apr-29-25 08:00AM	BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025 (GlobeNewswire) +11.35%
Apr-24-25 08:00AM	BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +19.86%
10:05AM	Loading…
Apr-23-25 10:05AM	BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +10.03%
Mar-28-25 12:45PM	Q4 2024 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
03:04AM	BioAtla Inc (BCAB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Mar-27-25 06:18PM	BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-20-25 08:00AM	BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings (GlobeNewswire)
Mar-19-25 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 (GlobeNewswire)
Jan-02-25 12:00PM	BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-20-24 09:00AM	BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points (GlobeNewswire) -41.82%
Dec-16-24 08:00AM	BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting (GlobeNewswire) -6.90%
08:00AM	Loading…
Dec-10-24 08:00AM	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic and Translational Science Meeting (GlobeNewswire)
08:00AM	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting (GlobeNewswire)
Nov-08-24 04:03PM	BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -5.41% +12.86%
Nov-07-24 04:01PM	BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire) +7.77%
Oct-31-24 08:00AM	BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 (GlobeNewswire)
Oct-20-24 04:06PM	BioAtla, Inc. (BCAB): Among Michael Burry's Top 10 Stock Picks Heading Into 2025 (Insider Monkey)
Oct-09-24 05:57PM	BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
Oct-04-24 09:05AM	BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -6.38%
Oct-01-24 08:00AM	BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress (GlobeNewswire)
Sep-23-24 07:30AM	BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody (GlobeNewswire)
Sep-16-24 08:00AM	BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting (GlobeNewswire) -7.18%
Sep-09-24 08:00AM	BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting (GlobeNewswire)
Aug-28-24 08:00AM	BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-08-24 04:05PM	Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire) +5.76%
Aug-01-24 08:00AM	BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024 (GlobeNewswire)
01:11PM	Loading…
Jul-31-24 01:11PM	These 2 Strong Buy Penny Stocks Are Poised for a Big Rally, Say Analysts (TipRanks) +11.04%
Jul-25-24 05:39PM	BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day (GlobeNewswire)
Jul-24-24 12:54PM	BioAtla receives FDA fast track designation for ozuriftamab vedotin (Pharmaceutical Technology)
Jul-23-24 08:00AM	BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (GlobeNewswire)
Jun-27-24 08:00AM	BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 (GlobeNewswire)
May-29-24 08:00AM	BioAtla to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -9.52%
May-23-24 05:05PM	BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.89% -18.57%
May-15-24 08:18AM	BioAtla, Inc. (NASDAQ:BCAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +14.94%
07:01AM	BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ... (GuruFocus.com)
May-14-24 08:57PM	BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire)
May-08-24 08:00AM	BioAtla to Participate in the Citizens JMP Life Sciences Conference (GlobeNewswire)
May-07-24 08:00AM	BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 (GlobeNewswire)
May-06-24 09:14AM	BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance (MT Newswires)
08:00AM	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors (GlobeNewswire)
Apr-24-24 04:35PM	BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-27-24 10:07AM	BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.95%
07:56AM	Q4 2023 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-26-24 09:54PM	BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023 (InvestorPlace) +29.18%
05:33PM	BioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-19-24 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024 (GlobeNewswire) +5.13%
Mar-07-24 08:00AM	BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Dec-20-23 08:00AM	BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 08:00AM	BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types (GlobeNewswire) +23.26%
Dec-06-23 08:00AM	BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023 (GlobeNewswire)
Dec-05-23 08:00AM	BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event (GlobeNewswire)
Nov-30-23 08:00AM	BioAtla to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:00AM	BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC (GlobeNewswire) +8.16%
Nov-12-23 09:24AM	BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:01PM	BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) -6.25%
Nov-06-23 04:05PM	BioAtla to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-12-23 07:30AM	BioAtla's Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award (GlobeNewswire) -5.46%
Oct-10-23 07:30AM	BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023 (GlobeNewswire) +15.12%
Sep-06-23 08:00AM	BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:01PM	BioAtla to Participate in Upcoming Investor Conferences in August (GlobeNewswire) -8.67%
06:48AM	BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-02-23 11:31AM	Q2 2023 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-23 04:01PM	BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Jul-25-23 08:00AM	BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023 (GlobeNewswire)
Jul-07-23 07:09AM	With 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional owners (Simply Wall St.)
Jun-26-23 08:00AM	BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index (GlobeNewswire) -9.43%
May-31-23 08:00AM	BioAtla to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +14.33%
May-08-23 04:05PM	BioAtla to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire) -9.44%
May-04-23 08:00AM	BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 (GlobeNewswire)
Apr-29-23 09:29AM	We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research) +8.94%
Mar-27-23 07:12AM	BioAtla, Inc. (NASDAQ:BCAB) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.51%
Mar-24-23 11:31AM	Q4 2022 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-23-23 04:05PM	BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-16-23 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights (GlobeNewswire)
Feb-27-23 08:07AM	BioAtla Announces Change in Executive Leadership (GlobeNewswire)
Feb-23-23 08:00AM	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma (GlobeNewswire) -8.83%
Jan-25-23 07:10AM	Recent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past year (Simply Wall St.) -5.39%
Jan-10-23 08:00AM	BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones (GlobeNewswire) -46.24%
Dec-29-22 04:05PM	Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors (PR Newswire)
Dec-22-22 08:00AM	BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 08:54AM	BioAtla, Inc.'s stock is down 11%, but insiders still have about US$393k in profit after buying earlier this year (Simply Wall St.)
Dec-01-22 09:55AM	Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect? (Zacks)
Nov-15-22 09:55AM	Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect? (Zacks) -7.47%
Nov-11-22 08:38AM	Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth (Simply Wall St.) +10.32%
Nov-08-22 08:00AM	BioAtla to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-22 11:15AM	BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +18.71%
09:08AM	BioAtla Announces $65 Million Underwritten Offering of its Common Stock (GlobeNewswire)
Nov-03-22 04:01PM	BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Oct-27-22 08:00AM	BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 (GlobeNewswire)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey) -5.76%
Sep-21-22 10:14AM	J.P. Morgan Says Stock Market Downside Risk Is Limited; Here Are 3 Stocks to Consider (TipRanks)
Sep-12-22 10:08AM	Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011) (PR Newswire) -7.12%

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

KTTA

Pasithea Therapeutics Corp

ATNF

180 Life Sciences Corp

BCAB

BioAtla Inc

Upgrade your FINVIZ experience